Genzyme Introduces “Chart Your Own Course” Scholarship Contest for the LSD Community

March 25, 2013

Genzyme, a pioneer of development and delivery of transformative therapies for over 30 years, has a new opportunity for the Lysosmal Storage Disorder Community. The innovative corporation is putting a further emphasis on patient education by launching “Chart Your Own Course”– a scholarship program aimed at putting a spotlight on the perserverance and dedication of students pursuing their education while dealing with rare disease.

What Is Chart Your Own Course?

Genzyme is excited to introduce Chart Your Own Course, a new program established to help students in the lysosomal storage disorder (LSD) community pursue their educational dreams! Our independent review committee will select eight qualified recipients who will each be awarded a $2,500 scholarship.

Who Is Eligible?

Anyone living with an LSD — regardless of treatment status — may apply for Chart Your Own Course. Applicants must be U.S. citizens or green card holders who will be full-time students in Fall 2013 at an accredited college, university, or vocational or trade school. Find out more about eligibility.

How Do I Apply?

Visit to get more details and download the application form. You’ll need to gather school transcripts and other details, obtain a personal reference and write some brief personal statements. Applications are due (must be postmarked) by April 30, 2013, and recipients will be announced in early June.

Please do not reply to this email; instead, visit for more information or call our program administrator at (507) 931-1682. You can also call your Genzyme case manager at (800) 745-4447.

Chart Your Own Course award recipients are selected by an independent review committee, and no Genzyme employees are involved in the review process. Genzyme has established eligibility criteria, and any changes to those criteria, to award amounts, or to other program details are at the discretion of Genzyme, a Sanofi Company.

Stay Connected

Sign up for updates straight to your inbox.